Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.

ABSTRACT:

Background

Although anti-tumor necrosis factor (TNF) agents are effective in patients with inflammatory bowel disease (IBD), many patients either do not respond to anti-TNF treatment or lose response over time. The aim of this study was to determine factors associated with response to anti-TNF therapy in IBD.

Methods

Patients with Crohn's disease (CD) or ulcerative colitis who had consented to participate in a genetics registry and been treated with anti-TNF agents were evaluated retrospectively and categorized as primary nonresponders or secondary nonresponders. We evaluated clinical, serological, and genetic characteristics associated with primary nonresponse or time to loss of response to anti-TNF agents.

Results

We included 314 CD (51 [16.2%] primary nonresponders

SUBMITTER: Yoon SM 

PROVIDER: S-EPMC6510223 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature